Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation
- 1 December 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 27 (13), 5161-5172
- https://doi.org/10.1245/s10434-020-08967-9
Abstract
Background. This study assessed patterns of failure and rates of subsequent biliary intervention among patients with resected biliary tract cancers (BTCs) including gallbladder carcinoma (GBC) and extra- and intrahepatic cholangiocarcinoma (eCCA and iCCA) treated with adjuvant chemoradiation therapy (CRT). Methods. In this single-institution retrospective analysis of 80 patients who had GBC (n = 29), eCCA (n = 43), or iCCA (n = 8) treated with curative-intent resection and adjuvant CRT from 2007 to 2017, the median radiation dose was 50.4 Gy (range 36-65 Gy) with concurrent 5-fluorouracil (5-FU) chemotherapy. All but two of the patients received adjuvant chemotherapy. The 2-year locoregional failure (LRF), 2-year recurrence-free survival (RFS), and 2-year overall survival (OS), and univariate predictors of LRF, RFS, and OS were calculated for the entire cohort and for a subgroup excluding patients with iCCA (n = 72). The predictors of biliary interventions also were assessed. Results. Of the 80 patients (median follow-up period, 30.5 months; median OS, 33.9 months), 54.4% had American Joint Committee on Cancer (AJCC) stage 1 or 2 disease, 57.1% were lymph node-positive, and 66.3% underwent margin-negative resection. For the entire cohort, 2-year LRF was 23.8%, 2-year RFS was 43.7%, and 2-year OS was 62.1%. When patients with iCCA were excluded, the 2-year LRF was 22.6%, the 2-year RFS was 43.9%, and the 2-year OS was 59.2%. In the overall and subgroup univariate analyses, lymph node positivity was associated with greater LRF, whereas resection margin was not. Biliary intervention was required for 12 (63.2%) of the 19 patients with LRF versus 11 (18%) of the 61 patients without LRF (P < 0.001). Of the 12 patients with LRF who required biliary intervention, 4 died of biliary complications. Conclusions. The LRF rates remained significant despite adjuvant CRT. Lymph node positivity may be associated with increased risk of LRF. Positive margins were not associated with greater LRF, suggesting that CRT may mitigate LRF risk for this group. An association between LRF and higher rates of subsequent biliary interventions was observed, which may yield significant morbidity. Novel strategies to decrease the rates of LRF should be considered.This publication has 70 references indexed in Scilit:
- Role of Adjuvant Chemoradiotherapy for Resected Extrahepatic Biliary Tract CancerInternational Journal of Radiation Oncology*Biology*Physics, 2011
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary CancersJournal of Clinical Oncology, 2011
- Genetics of Biliary Tract Cancers and Emerging Targeted TherapiesJournal of Clinical Oncology, 2010
- Surgical Treatment of Mass-Forming Intrahepatic Cholangiocarcinoma: An 11-Year Western Single-Center Experience in 107 PatientsAnnals of Surgical Oncology, 2008
- Indication for Postoperative Adjuvant Therapy in Biliary Carcinoma Based on Analysis of Recurrence and Survival After Surgical ResectionDigestive Diseases and Sciences, 2008
- Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic diseaseJournal of Surgical Oncology, 2007
- CholangiocarcinomaAnnals of Surgery, 2007
- Adjuvant Concurrent Chemoradiation for Adenocarcinoma of the Distal Common Bile DuctInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Treatment strategy for patients with middle and lower third bile duct cancerBritish Journal of Surgery, 2001
- Biliary Tract CancersNew England Journal of Medicine, 1999